Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIMERA trial of first-line trastuzumab deruxtecan + capecitabine + bevacizumab in HER2-positive metastatic colorectal cancer
2024-519479-24-00Phase 2Authorised
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan, capecitabine and bevacizumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Planned start Oct 2025; status: authorised.
02
Drugs
trastuzumab deruxtecancapecitabinebevacizumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2024-519479-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519479-24-00.